Background: Sparganosis is a parasitic infection caused by the plerocercoid larvae of Spirometra mansoni in East and Southeast Asia. The plerocercoid larvae sometimes invade the encephalon, resulting in severe cerebral sparganosis. Surgical removal of the larvae is considered a standard therapy for cerebral sparganosis. In contrast, the efficacy and safety of long-term, high-dose praziquantel treatment for cerebral sparganosis have not been explored.
Methodology/principal Findings: In this multicenter retrospective study, we assessed the records of 96 patients with cerebral sparganosis who consulted at three medical centers from 2013 to 2017. Forty-two patients underwent surgical lesion removal, and the other 54 patients received long-term, high-dose praziquantel (50 mg/kg/day for 10 days, repeated at monthly intervals). The primary outcome was the complete disappearance of active lesions on cerebral magnetic resonance imaging. The secondary outcomes included the modified Rankin scale score at 90 days, incidence of seizure, eosinophil count, and serological Spirometra. mansoni antibody titer. The efficacy of praziquantel treatment was similar to that of surgical lesion removal for cerebral sparganosis with respect to both the primary outcome and secondary outcomes. Although binary logistic regression models also supported the primary outcome after adjustment for age, sex, lesion location, and loss to follow-up, some unavoidable confounders might have biased the statistical power. No significant clinical complications or laboratory side effects occurred in the praziquantel group with the exception of a relatively benign allergic reaction.
Conclusions/significance: In this small-sample, nonrandomized, retrospective exploratory study, some patients with cerebral sparganosis were responsive to long-term, high-dose praziquantel with an efficacy similar to that of surgical lesion removal. These findings increase the treatment flexibility for this serious infection.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6211769 | PMC |
http://dx.doi.org/10.1371/journal.pntd.0006918 | DOI Listing |
Neurology
January 2025
From the Department of Neurosurgery (H.R.P.), Soonchunhyang University Seoul Hospital, Seoul; Department of Neurosurgery (S.H.P.), Cancer Research Institute, Hypoxia Ischemia Disease Institute, Seoul National University, Seoul; and Advanced Institutes of Convergence Technology (S.H.P.), Seoul National University, Suwon, Republic of Korea.
Narra J
August 2024
Department of Parasitology and Mycology, Faculty of Medicine, Universitas Sebelas Maret, Surakarta, Indonesia.
Ann Indian Acad Neurol
July 2024
Department of Neurology, National Institute of Mental Health and Neurosciences, Bangalore, Karnataka, India.
Indian J Med Microbiol
June 2023
Parasitic Disease Research Center, Suranaree University of Technology, Nakornratchasrima, Thailand; Joesph Ayobabalola University, Ikeji-Arakeji, Nigeria.
BMC Infect Dis
May 2023
Department of Radiology, Guangzhou Women and Children's Medical Centre, Guangzhou, China.
Background: Invasion of the corpus callosum by sparganosis is rare in children. After invading the corpus callosum, sparganosis has various migration modes, which can break through the ependyma and enter the ventricles, thus causing secondary migratory brain injury.
Case Presentation: A girl aged 4 years and 7 months presented with left lower limb paralysis for more than 50 days.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!